Introduction: Acromegaly is a quite rare chronic disease caused by the increased secretion of growth hormone (GH) and subsequently insulin -like growth factor 1. Although cardiovascular diseases remains the most common cause of mortality among acromegalic patients, increased prevalence of malignant and benign neoplasms remains a matter of debate. The aim of this study is to evaluate the risk of thyroid nodular disease (TND) and thyroid cancer in patients with acromegaly.
Introduction
Acromegaly is a rare chronic disease caused by the increased secretion of growth hormone (GH) and subsequently insulin-like growth factor 1 (IGF-1) [1, 2] . Cardiovascular diseases are very common and remain the most common cause of mortality among acromegalic patients [2, 3] . However, increased prevalence of malignant and benign neoplasms is also a matter of debate [2, 4] . Most studies were focused on colorectal and thyroid tumors, however also elevated risk of other, e.g. breast, central nervous system, adrenals or urinary tract neoplasm were reported [2, 4, 5, 6, 7, 8] . Meta-analysis performed by Rokkas et al. [5] proved the increased risk of colon cancer. The issue of benign and malignant thyroid tumors is not as well established as there was no meta-analysis on the topic and outcomes of particular studies were dispersed.
The aim of this study is to evaluate the risk of thyroid nodular disease (TND) and thyroid cancer (TC) in patients with acromegaly and also to combine results of the studies including control groups to assess if the risk is significantly higher than in general population.
Materials and Methods

Selection of the Studies
We have searched the PubMed/MEDLINE, Cochrane Library, Scopus, Cinahl, Academic Search Complete, Web of Knowledge, PubMed Central, PubMed Central Canada and Clinical Key databases from January 1960 up to May 2013 in order to find all relevant journal articles. We have used the search term: acromegaly and (thyroid or ''thyroid cancer'' or ''thyroid nodules'' or goitre). Only full-text journal articles written in English were taken into account. We have also searched manually the references of review articles in order to avail eventually omitted studies. Two researchers (K.W., A.C.) searched all included databases independently and prepared list of included studies. In case of discrepancies between lists, authors were reading doubtful articles together.
Data Extraction
We have recorded data on study design, year of publication, country of origin, number of the patients, sex and age of participants, duration of the disease, methods of the thyroid examination (e.g. ultrasonography, palpation), number of patients with and without thyroid lesions and with thyroid cancer. In case of studies including control group, same data on this group were recorded. Studies with control group matched by age and sex was included. Studies with control groups not matched by this parameters were excluded to avoid within study bias.
Statistical Analysis
We have meta-analyzed odds ratios (OR) and risk ratios (RR) using a random -effect model using Statistica v.10 software with medical package. Heterogeneity between studies was assessed using the Q statistics and I2 statistics. Q and i 2 values given in ''Results'' are based on the odds ratio calculations. If calculation of OR was impossible due to zero cells, a constant (0.5) were added to all columns. Publication bias was assessed using Kendall's tau. If publication bias was present we performed cumulative metaanalysis and also re-performed calculations with exclusion of the studies with highest standard error. We used also data from all included studies (with and without control groups) to calculate the pooled prevalence of thyroid nodular disease (TND) and thyroid cancer (TC) as well as malignancy rates. These data were metaanalyzed using random -effect model according to the methodology described by Borenstein et al. [9] . Only studies assessing the thyroid by ultrasonographic (US) examination were included in calculations concerning TND. Other articles (e.g. about palpable nodules only) have been systematically reviewed.
Results
Case -control Studies
The search results and steps of selection are shown on the flowchart (figure 1). Nine studies including control group were identified. In one of them [10] only palpational examination of thyroid was performed. In one study [11] the control group was not matched by age and BMI, in another one -such details about control group were not given [12] . In study performed by Cannavo et al. [13] control group was not matched by sex. These four studies were excluded from the meta-analysis. Another five studies, two prospective and three retrospective have been included. [table 1] In case of 15 studies only data on prevalence of thyroid lesions or thyroid cancer were available (without data on the control groups). These studies were included in quantitative synthesis of pool prevalence of thyroid lesions. Two studies contained data on palpable nodules only; these studies were systematically reviewed.
For thyroid nodules the pooled OR was 3.6 with 95% confidence interval (CI) 1.8-7.4 [ fig. 2 , table 2], RR = 2.1, 95% CI 1.3-3.3. There were no evidences for significant heterogeneity (Q = 1.8, degrees of freedom (df) = 2, p value = 0.40; i2 = 0.0%). There is no evidence for publication bias (Kendall's tau = 0.33, two -tailed p value = 0.60).
For thyroid cancers the pooled OR was 7.9 (95% CI 2.8-22.0) [ fig. 3, table 3 ], RR = 7.6 (95% CI 2.7-20.8). There are no evidences for significant heterogeneity (Q = 2.5, degrees of freedom (df) = 4, p value = 0.65; i2 = 0.0%). There is no evidence for publication bias (Kendall's tau = 0.80, two -tailed p value = 0.05). However, the calculations of publication bias was of borderline statistical significance. Exclusion of the study with the highest standard error [15] would slightly decrease the pooled result (OR 6.7) and it would eliminate this borderline publication bias (Kendall's Tau 0.67, p = 0.17). Cumulative metaanalysis was shown on figure 4 [figure 4 ].
Studies without Control Group
Results of studies which did not include control group or included groups which were excluded from the meta-analysis according to some methodological doubts (e.g. control group not matched by age) are shown in table 4 [table 4 ].
Eleven studies were included. Using also the data about prevalence from case -control studies, there were 13 papers containing data on TND frequency in ultrasound (US) examination and also 13 bringing data on thyroid cancer occurrence. Two further studies contained information about palpable thyroid nodules.
Prevalence of thyroid lesions fluctuated from 43.2% to 75.6% in US examination. In total there were 668 patients with and 457 without TND included. The pooled prevalence meta-analyzed using random -effect model is equal to 59.2% with 95% CI 52.7% -66.5%.
In two studies about the prevalence of palpable thyroid nodules was given in two papers and it was 38.8 and 10.5%.
Prevalence of TC fluctuated from 0.8% to 11.8%. In total there were 55 patients with and 1317 without TC included. The pooled prevalence meta-analyzed using random -effect model is equal to 4.3% with 95% CI 3.0% -6.2%.
Register -based Studies
Four studies based on registers of acromegalic patients and cancer patients were identified [ 
Malignancy Rate in Thyroid Nodules
Ten studies included data both on thyroid nodules and thyroid cancer frequency what allows to calculate the risk of malignancy in acromegalic patients with TND. There were 620 patients with TND including 48 malignancies. The pooled rate of malignancy (calculated per patient) meta-analyzed using random -effect model is equal to 8.7% with 95% CI 6.1% -12.3%. Comparing the risk of malignancy in the studies containing control group, the RR of malignancy in patients with TND and acromegaly was insignificantly higher than in patients with TND and without acromegaly -RR = 3.2, 95% CI 0.5-20.1.
Discussion
Thyroid nodular disease turned out to be significantly more frequent in patients with acromegaly than in control groups (OR = 3.6, RR = 2.1) and it seems to be a very common disorder in these patients (prevalence slightly below 60%). According to Wüster et al. [10] also palpable thyroid nodules occurs significantly more often in acromegalic patients TC also proved to be more common in acromegaly (OR = 7.9, RR = 7.6), however the calculations of publication bias was of borderline significance (p = 0.05), what can suggest slight overestimation of the result. Prevalence of TC was quite high -about 4%. The risk of malignancy in acromegalic patients with TND was insignificantly higher than in control groups. There was also visible tendency that in newer studies thyroid disorders are reported more frequentlye.g. in studies published from 2008 TND occurred in about 65% of patients whereas in older studies -in about 54%; similar tendency can be observe in case of TCs -they were present in almost 6% of patients in papers published from 2008 and about 3% in older studies. This result is in line with suggestions, that the improving diagnostic and treatment of acromegaly extends the life duration what increases the prevalence of benign and malignant neoplasms. In the past, more patients died before neoplasms appeared or became clinically relevant [4] . The fact that our metaanalysis includes study performed in the period of over 50 years could be consider as limitation of this research. On the second, Table 4 . Studies without control group or with control group exluded from meta-analysis. Kurimoto et al. [24] Palpable nodules only. 5 11 patients examined only by palpation were excluded; descriptive statistics refer to the whole group; Abbreviations: SD -standard deviation; SIR -standarized incidence ratio; TC -thyroid cancer; TND -thyroid nodular disease. doi:10.1371/journal.pone.0088787.t004
however there were numerable studies on the topic, amount of most reliable papers -prospective, including sex and age matched control groups and data both on the prevalnce of TC and TND is unsatisfactory. This fact is another limitation of this meta-analysis and it causes that confidence intervals of ORs and RRs are very wide, it also precludes detailed analysis of case -control studies in subgroups (e.g. newer vs. older studies). It also calls attention that studies based on matching data from registers of acromegalic patients with data from cancer registers showed much lower frequency of TC than other, especially prospective studies, however in most cases insignificantly higher than expected [31, 32] . This discrepancy can be partially caused by inaccuracies in registers. On the other hand, these results may suggest, that TCs remained undiagnosed in great proportion.
In included studies the risk of malignancy for patients with TND was about 8%, what is in the range considered for general population [34] . Case -control studies also did not show significantly increased risk. However, the amount of studies is unsatisfactory; further researches are necessary to determine, if the risk of malignancy in acromegalic patients with TND is higher than in general population or if the frequency of TC is elevated proportionally to increased prevalence of TND.
However, many studies was published on the topic of increased risk of benign and malignant neoplasms in acromegaly, it remains controversial as results were often divergent. Among neoplasms, the increased prevalence of colon polyps and cancer seems to be most widely agreed, in large part thanks to meta-analysis performed by Rokkas et al. [5] . Comparing results of that metaanalysis with our outcomes, the risk of TC is elevated even more strongly than the risk of colon cancer (OR 7.9 vs. 4.4). Prevalence of these two malignancies seems to be similar in acromegalic patients, about 4.5%.
In conclusion, our meta-analysis proved that patients with acromegaly are at an increased risk of thyroid nodular disease and thyroid cancer. These results indicate, that periodic thyroid US examination and careful evaluation of eventual lesions should be important part of follow-up of acromegalic patients.
This study was performed with concorance with the PRISMA statement [35] .
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